维思通、氯氮平合并碳酸锂治疗躁狂症临床对照研究  

A clinical control study of risperidone and clozapine combined with lithium in treatment of mania.

作　　者：王元秀[1] 任泽华[1] 宋磊[1] 陈红生[1] 伊茂森[1] 

机构地区：[1]山东省滨州市人民医院精神卫生中心,256613

出　　处：《山东精神医学》2003年第1期24-25,共2页Shangdong Archives of Psychiatry

摘　　要：目的 观察维思通与氯氮平分别合并碳酸锂治疗躁狂症的疗效和副反应。方法 将符合CCMD-2-R诊断标准的60例躁狂症患者,随机分为两组,在使用碳酸锂的基础上分别合并维思通或氯氮平进行为期6周的治疗。使用躁狂量表(BRMS)及临床疗效总评量表评定疗效,使用TESS评定副反应。结果 维思通组与氯氮平组疗效相当,总有效率分别为90％,93.3％,维思通组起效时间迟于氯氮平组,但副反应较轻,依从性好。结论 维思通合并碳酸锂与氯氮平合并碳酸锂治疗躁狂症总体疗效相当,虽起效稍迟,但安全性高,患者易接受。Objective To compare the efficacy and side effects of risperidone and clozapine both combined with lithium in mania. Methods Sixty patients meeting the criteria of CCMD-2-R for maina were randomly assigned to receive risperidone or clozapine both combined with lithium for 6 weeks. Clinical efficacy and side effects were evaluated with Bech-Rafaelsen mania rating scale(BRMS) and treatment emergent symptom scale (TESS) separately. Results The improvement rate in risperidone group was 90 % and that in clozapine group was 93. 3%. No significant difference was found in two groups. The time of taking into effect in risperidone group was later than that in clozapine group. Risperidone showed lewer side effects. Conclusion Risperidone combined with lithium was as effective as clozapine plus lithium in mania,and easily accepted by patients because of higher security.

关 键 词：躁狂症 维思通 氯氮平 碳酸锂 

分 类 号：R749.41[医药卫生—神经病学与精神病学]